Table 2. Associations of BNT162b2 Third Dose Vaccination With SARS-CoV-2 Infection, COVID-19 Hospitalization, and Death More Than 7 Days Following Vaccination Among Residents of Long-term Care Facilities.

End Point	No. of residents	No. of cases	Cumulative incidence %	Unadjusted HR (95% CI)a	P valuea	Adjusted HR (95% CI)b	P valueb
RT-PCR confirmed SASR-CoV-2 infection
2 Doses of BNT162b2 vaccinec	2529	185	7.5	1 [Reference]	<.001	1 [Reference]	<.001
3 Doses of BNT162b2 vaccine	16 082	107	0.7	0.10 (0.07-0.15)		0.11 (0.07-0.15)
Mild/moderate COVID-19 hospitalization
2 Doses of BNT162b2 vaccinec	2517	96	3.9	1 [Reference]	<.001	1 [Reference]	<.001
3 Doses of BNT162b2 vaccine	16 080	27	0.2	0.08 (0.04-0.15)		0.07 (0.03-0.14)
Severe COVID-19 hospitalization
2 Doses of BNT162b2 vaccinec	2529	66	2.7	1 [Reference]	<.001	1 [Reference]	<.001
3 Doses of BNT162b2 vaccine	16 082	14	0.1	0.09 (0.04-0.22)		0.10 (0.04-0.24)
COVID-19–related deathsd
2 Doses of BNT162b2 vaccinec	2529	22	0.9	1 [Reference]	<.001	1 [Reference]	<.001d
3 Doses of BNT162b2 vaccine	16 082	5	0.04	0.03 (0.009-0.15)		0.04 (0.009-0.16)d

Abbreviation: HR, hazard ratio.

^a Unadjusted Cox regression models.

^b Multivariable Cox regression model, adjusted for the variables age, sex, community-level socioeconomic status rank, population group, and epidemiological week.

^c The second dose was administered at least 5 months before the follow-up start date.

^d Multivariable Cox regression model, adjusted for the variables age, sex, and epidemiological week.